Edition:
United Kingdom

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

113.83USD
16 Nov 2018
Change (% chg)

$1.63 (+1.45%)
Prev Close
$112.20
Open
$111.67
Day's High
$114.30
Day's Low
$111.67
Volume
1,381,177
Avg. Vol
1,012,158
52-wk High
$116.61
52-wk Low
$73.70

Select another date:

Tue, Jul 24 2018

Deals of the day-Mergers and acquisitions

July 24 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

Lilly plans Elanco IPO, posts quarterly profit above estimates

Eli Lilly and Co said on Tuesday it would take its Elanco animal health business public and posted a better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.

Eli Lilly posts quarterly loss

July 24 Eli Lilly and Co posted a second-quarter loss on Tuesday, hurt by acquisition-related charges to the tune of $1.62 billion.

Pfizer-Lilly pain drug meets late-stage trial goals

An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids.

Pfizer-Lilly pain drug found effective in late-stage study

July 18 An experimental drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of reducing pain in osteoarthritis patients in a late stage trial, the companies said on Wednesday.

Novo reveals more Ozempic data on change in body weight by baseline BMI

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.

UPDATE 2-Lilly gets U.S. nod for arthritis drug, sets price well below rivals

* Drug priced at $25,000/year, 60 pct lower to AbbVie's Humira

Novo Nordisk's oral diabetes drug beats Jardiance in study

LONDON, May 29 An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.

Select another date: